Cardiology News: PCSK9 Inhibitors
by Seth J. Baum MD Recently, there have been several articles discussing the development, efficacy, cost and long-term impact of novel cholesterol lowering drugs – called PCSK9 inhibitors – new.. read more
by Seth J. Baum MD Recently, there have been several articles discussing the development, efficacy, cost and long-term impact of novel cholesterol lowering drugs – called PCSK9 inhibitors – new.. read more
by Seth J. Baum, MD A recent article by Caroline Humer and Ransdell Pierson for Reuters reported on the unexpectedly paltry number of prescriptions for PCSK9 inhibitors, the revolutionary cholesterol.. read more
by Seth J. Baum, MD It was not long ago when doctors were the stopping point for the proverbial “buck.” Doctors held a high position in society and their devotion.. read more
by Seth J. Baum, MD Flying back from the FH Foundation’s third annual FH Summit I was suffused by assorted feelings and thoughts. I attend many meetings; yet, this one.. read more
by Seth J. Baum, MD It’s National Cholesterol Education Month and we have fittingly entered a new era in lipid management. We now know that elevated LDL cholesterol causes heart.. read more